In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disease progression or the participants are unable to tolerate the study drugs. Total, our current work highlights the potential utilization of ARV-825 in combination with https://abbv-744-brd4-inhibition70146.blogspothub.com/31231588/little-known-facts-about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers